- Home
- ARDC vs RIGL Comparison
ARDC vs RIGL Comparison
Compare ARDC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDC
- RIGL
- Stock Information
- Founded
- ARDC 2012
- RIGL 1996
- Country
- ARDC United States
- RIGL United States
- Employees
- ARDC N/A
- RIGL N/A
- Industry
- ARDC Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ARDC Finance
- RIGL Health Care
- Exchange
- ARDC Nasdaq
- RIGL Nasdaq
- Market Cap
- ARDC 336.6M
- RIGL 335.5M
- IPO Year
- ARDC N/A
- RIGL 2000
- Fundamental
- Price
- ARDC $14.12
- RIGL $18.70
- Analyst Decision
- ARDC
- RIGL Buy
- Analyst Count
- ARDC 0
- RIGL 5
- Target Price
- ARDC N/A
- RIGL $36.40
- AVG Volume (30 Days)
- ARDC 115.8K
- RIGL 170.2K
- Earning Date
- ARDC 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- ARDC 9.84%
- RIGL N/A
- EPS Growth
- ARDC N/A
- RIGL N/A
- EPS
- ARDC N/A
- RIGL 2.08
- Revenue
- ARDC N/A
- RIGL $203,077,000.00
- Revenue This Year
- ARDC N/A
- RIGL $14.41
- Revenue Next Year
- ARDC N/A
- RIGL $15.97
- P/E Ratio
- ARDC N/A
- RIGL $8.92
- Revenue Growth
- ARDC N/A
- RIGL 70.16
- 52 Week Low
- ARDC $11.56
- RIGL $7.48
- 52 Week High
- ARDC $14.30
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- ARDC 50.71
- RIGL 39.94
- Support Level
- ARDC $14.06
- RIGL $18.35
- Resistance Level
- ARDC $14.36
- RIGL $21.51
- Average True Range (ATR)
- ARDC 0.13
- RIGL 0.91
- MACD
- ARDC -0.02
- RIGL -0.32
- Stochastic Oscillator
- ARDC 29.41
- RIGL 8.43
About ARDC Ares Dynamic Credit Allocation Fund Inc.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.